Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
13.66
Nov 20 • 3:59 PM ET Dollar change-1.20 Percentage change(-8.08%)
Aftermarket Close
14.16
Aftermarket • 4:21 PM ET Dollar change+0.50 Percentage change(3.66%)
Today, 4:05 PMSELLAS closed its public offering, raising $172.5 million gross after underwriters fully exercised their option for additional shares.
Index
RUT
Market Cap
2.78B
Enterprise Value
2.65B
Income
-35.76M
Sales
0.00M
Book/sh
0.65
Cash/sh
0.66
Employees
13
IPO
Mar 12, 2008
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
21.09
P/C
20.66
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
14.92
Current Ratio
14.92
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-0.20
EPS next Y
-0.24
EPS next Q
-0.05
EPS this Y
20.00%
EPS next Y
-22.50%
EPS next 5Y
56.91%
EPS past 3/5Y
51.28% 34.92%
Sales past 3/5Y
- -
EPS Y/Y TTM
30.50%
Sales Y/Y TTM
-
EPS Q/Q
20.45%
Sales Q/Q
-
Insider Own
1.11%
Insider Trans
0.00%
Inst Own
35.44%
Inst Trans
5.10%
ROA
-37.13%
ROE
-40.31%
ROIC
-27.13%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
29.52%
SMA50
22.44%
SMA200
50.91%
Trades
Shs Outstand
203.53M
Shs Float
201.59M
52W High
24.89 -45.12%
52W Low
1.39 882.73%
Volatility
24.98% 14.10%
ATR (14)
2.36
RSI (14)
56.48
Beta
2.37
Rel Volume
1.58
Avg Volume
9.61M
Volume
15,197,651
Perf Week
73.79%
Perf Month
20.35%
Perf Quarter
-4.64%
Perf Half Y
75.58%
Perf YTD
262.33%
Perf Year
835.62%
Perf 3Y
1291.61%
Perf 5Y
94.86%
Perf 10Y
-99.75%
Prev Close
14.86
Price
13.66
Change %
-8.08%
Consensus
Strong Buy
Avg. Price Target
$37.50
Implied Upside
+174.5%
Analysts4incl. previous ratings
Rating Distribution4 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 21, 2021Initiated
CCantor Fitzgerald
Overweight$18+31.8%
Nov 01, 2018Initiated
OPY logoOOppenheimer
Outperform
Apr 02, 2018Initiated
HH.C. Wainwright
Buy$11-19.5%
Mar 19, 2018Upgrade
MMaxim Group
Hold → Buy$13-4.8%
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
ScD h.c.Dr. Angelos M. Stergiou M.D.
Senior VP & CFOMr. John Thomas Burns CPA
MBADr. Dragan Cicic M.D.
VPMs. Stacy E. Yeung
Senior VP of Regulatory AffairsMr. Andrew Elnatan